Erbitux Has Expanded Potential
Furthermore, patients in the Erbitux arm had two- and three-year survival rates of 62% and 57%, respectively, compared to respective two- and three-year survival rates of 55% and 44% for patients in the radiation-only arm.
"The use of cetuximab [Erbitux] and radiation therapy may become an excellent choice of therapy for this group of patients," Dr. James Bonner, a radiation oncologist at the University of Alabama and the lead investigator of the study, said in a statement. "Future studies should be performed to examine combinations of chemotherapy, radiation therapy and cetuximab [Erbitux]."
Saturday's data presentation was conducted by ASCO for journalists as part of a media briefing highlighting medical advances in lung and head and neck cancer. A full airing of this Erbitux data in front of the attendees at ASCO's annual meeting is scheduled for Tuesday.
One hitch in this Erbitux study is that it was started in 1999, and since then, doctors have altered the way they treat patients with so-called front-line, advanced head and neck cancer. Instead of using radiation alone, the standard of care is now the combination of radiation and chemotherapy. Since the study did not include the use of chemotherapy, ImClone may find it difficult to use the study as the basis for a new FDA approval filing.Still, given the survival benefit driven by Erbitux, doctors are likely to use the drug "off label," especially in head and neck cancer patients who can't tolerate chemotherapy. Some doctors may also assume that if radiation and chemotherapy work, then a triple combination of radiation, chemotherapy and Erbitux will work even better. There has been data presented at past ASCO meetings that showed evidence of Erbitux and chemotherapy working synergistically in head and neck cancer, just like it does in colon cancer.
Select the service that is right for you!COMPARE ALL SERVICES
Jim Cramer and Stephanie Link actively manage a real portfolio and reveal their money management tactics while giving advanced notice before every trade.
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
Jim Cramer's protege, David Peltier, identifies the best of breed dividend stocks that will pay a reliable AND significant income stream.
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
All of Real Money, plus 15 more of Wall Street's sharpest minds delivering actionable trading ideas, a comprehensive look at the market, and fundamental and technical analysis.
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
Our options trading pros provide daily market commentary and over 100 monthly option trading ideas and strategies to help you become a well-seasoned trader.
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV